{
  "first_published_at": "2014-01-14", 
  "original_url": "http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON364156", 
  "title": "Prasugrel (Efient): increased risk of bleeding—information on timing of loading dose", 
  "tags": "{\"parsed_therapeutic\": [\"anaesthesia-intensive-care\", \"cardiovascular-disease-lipidology\"], \"Audience:\": [\"Secondary care\"], \"Therapeutic area:\": [\"Anaesthesia and intensive care\", \"Cardiovascular disease and lipidology\"]}", 
  "_document_number": 43, 
  "label": null, 
  "icon": "http://www.mhra.gov.uk/home/images/MHRALook/img/dsu/dose_icon.png", 
  "therapeutic_area": [
    "anaesthesia-intensive-care", 
    "cardiovascular-disease-lipidology"
  ], 
  "raw_html": "<div id=\"dsuArticleContent\">\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\t<h1><a name=\"maincontent\" id=\"maincontent\"></a>Prasugrel (Efient): increased risk of bleeding&#8212;information on timing of loading dose</h1>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<span class=\"ref\">Article date: January 2014</span> \r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t<!--New clinical trial information is available on the timing of the loading dose of prasugrel when used in patients with unstable angina or non-ST segment elevation myocardial infarction.-->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<div id=\"dsuSynopsis\" class=\"yellow\">\r\n\t\t\t\t\t\t\t\t\t<div class=\"dsuArticlePadding\">\r\n\t\t\t\t\t\t\t\t\t<span id=\"dsuSynopsisTitle\"><b>Summary</b></span>\t\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\t<br><p>New clinical trial information is available on the timing of the loading dose of prasugrel when used in patients with unstable angina or non-ST segment elevation myocardial infarction.</p>\n\n<p>In these patients, when coronary angiography is done within 48 hours after admission, the loading dose should only be given at the time of percutaneous coronary intervention. This is to minimise the risk of bleeding.</p><br>\t\r\n\t\t\t\t\t\t\t\t\t</div>         \t\t\r\n\t\t\t\t\t\t\t\t\t<div id=\"dsuSynopsisCut\">\r\n\t\t\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t<!--<p>Prasugrel (Efient) is a member of the thienopyridine class of medicines, and it inhibits platelet activation and aggregation. Prasugrel is indicated, in combination with aspirin, for the prevention of atherothrombotic events in patients with acute coronary syndrome undergoing primary or delayed percutaneous coronary intervention (PCI).</p>\n\n<p>The licensed dose of prasugrel is a loading dose of 60 mg, followed by 10 mg (or 5 mg, see advice below) once a day. Treatment for up to 1 year is recommended, unless discontinuation is clinically indicated. The appropriate timing of the loading dose in patients with non-ST segment elevation myocardial infarction (NSTEMI) or unstable angina has now been clarified as a result of new data from the ACCOAST trial.<cite>Montelascot G, for the ACCOAST trial investigators. N Engl J Med 2013; 369: 999&#8211;1010</cite></p>\n\n<p>ACCOAST was a randomised trial of about 4000 NSTEMI patients that compared the effects of prasugrel loading dose of 30 mg before coronary angiography and a further 30 mg dose at the time of PCI, with that of a loading dose of 60 mg given at the time of PCI.</p>\n\n<p>The trial found an increased risk of bleeding but no additional benefit in the experimental, split loading-dose group compared with those who received 60 mg at the time of PCI.</p>\n\n<div class=\"dull_highlight\">\n<p><strong>Advice for healthcare professionals:</strong></p>\n\n<ul>\n<li>Prasugrel is approved as a single 60 mg loading dose (followed by a maintenance dose recommended for up to 1 year); this remains unchanged</li>\n\n<li>Patients with unstable angina or NSTEMI, who undergo coronary angiography within 48 hours of admission, should be given a loading dose of 60 mg at the time of PCI only, to minimise bleeding risk</li>\n\n<li>Remember that a reduced maintenance dose of 5 mg once daily should be used (recommended for up to 1 year) if patients are age 75 years or older, or if their bodyweight is less than 60 kg</li>\n</ul>\n</div>\n\n<p><strong>Further information</strong></p>\n\n<p>See letter for healthcare professionals <a href=\"http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/CON364176\" target=\"_blank\">sent in December 2013</a></p>\n\n<p><em>Article citation: Drug Safety Update volume 7 issue 6, January 2014: A1.</em></p>-->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_BEGIN_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t\t<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n\t<p>Prasugrel (Efient) is a member of the thienopyridine class of medicines, and it inhibits platelet activation and aggregation. Prasugrel is indicated, in combination with aspirin, for the prevention of atherothrombotic events in patients with acute coronary syndrome undergoing primary or delayed percutaneous coronary intervention (PCI).</p>\n\n<p>The licensed dose of prasugrel is a loading dose of 60 mg, followed by 10 mg (or 5 mg, see advice below) once a day. Treatment for up to 1 year is recommended, unless discontinuation is clinically indicated. The appropriate timing of the loading dose in patients with non-ST segment elevation myocardial infarction (NSTEMI) or unstable angina has now been clarified as a result of new data from the ACCOAST trial.<cite>Montelascot G, for the ACCOAST trial investigators. N Engl J Med 2013; 369: 999&#8211;1010</cite></p>\n\n<p>ACCOAST was a randomised trial of about 4000 NSTEMI patients that compared the effects of prasugrel loading dose of 30 mg before coronary angiography and a further 30 mg dose at the time of PCI, with that of a loading dose of 60 mg given at the time of PCI.</p>\n\n<p>The trial found an increased risk of bleeding but no additional benefit in the experimental, split loading-dose group compared with those who received 60 mg at the time of PCI.</p>\n\n<div class=\"dull_highlight\">\n<p><strong>Advice for healthcare professionals:</strong></p>\n\n<ul>\n<li>Prasugrel is approved as a single 60 mg loading dose (followed by a maintenance dose recommended for up to 1 year); this remains unchanged</li>\n\n<li>Patients with unstable angina or NSTEMI, who undergo coronary angiography within 48 hours of admission, should be given a loading dose of 60 mg at the time of PCI only, to minimise bleeding risk</li>\n\n<li>Remember that a reduced maintenance dose of 5 mg once daily should be used (recommended for up to 1 year) if patients are age 75 years or older, or if their bodyweight is less than 60 kg</li>\n</ul>\n</div>\n\n<p><strong>Further information</strong></p>\n\n<p>See letter for healthcare professionals <a href=\"http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/CON364176\" target=\"_blank\">sent in December 2013</a></p>\n\n<p><em>Article citation: Drug Safety Update volume 7 issue 6, January 2014: A1.</em></p>\r\n\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_END_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t", 
  "date_of_article": "2014-01-01", 
  "date_last_modified": "2014-01-20", 
  "_assets": [], 
  "_item_id": 43, 
  "summary": "New clinical trial information is available on the timing of the loading dose of prasugrel when used in patients with unstable angina or non-ST segment elevation myocardial infarction.\n\nIn these patients, when coronary angiography is done within 48 hours after admission, the loading dose should only be given at the time of percutaneous coronary intervention. This is to minimise the risk of bleeding.", 
  "body": "Article date: January 2014\n\nPrasugrel (Efient) is a member of the thienopyridine class of medicines, and it inhibits platelet activation and aggregation. Prasugrel is indicated, in combination with aspirin, for the prevention of atherothrombotic events in patients with acute coronary syndrome undergoing primary or delayed percutaneous coronary intervention (PCI).\n\nThe licensed dose of prasugrel is a loading dose of 60 mg, followed by 10 mg (or 5 mg, see advice below) once a day. Treatment for up to 1 year is recommended, unless discontinuation is clinically indicated. The appropriate timing of the loading dose in patients with non-ST segment elevation myocardial infarction (NSTEMI) or unstable angina has now been clarified as a result of new data from the ACCOAST trial.[^1]\n\nACCOAST was a randomised trial of about 4000 NSTEMI patients that compared the effects of prasugrel loading dose of 30 mg before coronary angiography and a further 30 mg dose at the time of PCI, with that of a loading dose of 60 mg given at the time of PCI.\n\nThe trial found an increased risk of bleeding but no additional benefit in the experimental, split loading-dose group compared with those who received 60 mg at the time of PCI.\n\nAdvice for healthcare professionals:  \n  \n  * Prasugrel is approved as a single 60 mg loading dose (followed by a maintenance dose recommended for up to 1 year); this remains unchanged  \n  * Patients with unstable angina or NSTEMI, who undergo coronary angiography within 48 hours of admission, should be given a loading dose of 60 mg at the time of PCI only, to minimise bleeding risk  \n  * Remember that a reduced maintenance dose of 5 mg once daily should be used (recommended for up to 1 year) if patients are age 75 years or older, or if their bodyweight is less than 60 kg  \n  \nFurther information\n\nSee letter for healthcare professionals [sent in December 2013](http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/CON364176)\n\nArticle citation: Drug Safety Update volume 7 issue 6, January 2014: A1.\n\n[^1]: Montelascot G, for the ACCOAST trial investigators. N Engl J Med 2013; 369: 999–1010\n"
}